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ABSTRACT
A COMPARISON OF MYOFASCIAL RELEASE 
AND ULTRASOUND IN THE 
TREATMENT OF MUSCULOSKELETAL PAIN
Tory L. Bishop 
Old Dominion University, 1987 
Advisor: Dr. John L. Echternach
The purpose of this study was to evaluate the 
effectiveness of myofascial release (MFR) compared to 
ultrasound (US) in treating musculoskeletal pain. Thirty- 
three subjects with a mean age of 38 years were admitted to 
the study. Twenty-eight of the subjects were randomly 
placed into either the myofascial release or the ultrasound 
treatment group, and five of the subjects were placed into 
a treatment group based on referral by a physician. Each 
subject received 10 treatments. Data in the form of number 
of trigger points, active range-of-motion of the affected 
joint, pain scale measurement, and a Treatment Response 
Questionnaire score, were collected.
The t value for between group pre trigger point number 
supported statistical significance. The t value for 
between group post trigger point number supported no 
statistical significance. The t values for within group 
changes in trigger point supported no statistical 
significance. The Mann-Whitney U value supported that the
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MFR group outranked the US group 47 percent when ranking 
the percent change in trigger point number from pre to post 
treatment at a .05 level of significance. The Kruskal- 
Wallis H value for percent change in trigger point from pre 
to post treatment supported that MFR subjects appeared to 
make greater improvement than the US subjects at a .05 
level of significance.
The Mann-Whitney U value supported that the MFR group 
outranked the US group 79 percent when ranking the percent 
change in pain scale measurement from pre to post treatment 
at a .05 level of significance. Kruskal-Wallis H value for 
percent change in pain scale measurement from pre to post 
treatment supported that MFR subjects appeared to make a 
greater improvement than the US subjects at a .05 level of 
significance.
The Mann-Whitney U value supported that the MFR group 
outranked the US group 46 percent when ranking the change 
in range-of-motion from pre to post treatment at a .05 
level of significance. Confidence interval calculations 
showed that between group pre range-of-motion means and 
between group post range-of-motion means are not 
statistically significant at .05 level of significance. 
The difference in change of range-of-motion between the 
treatment groups is statistically significant at .05 level 
of significance in favor of the MFR group. The mean 
percent change in range-of-motion within each group is 
markedly different from each other, but standard deviations
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
are substantially large to question whether the results 
support one treatment over the other.
The Mann-Whitney U value supported that the MFR group 
outranked answers in the US group 55 times at a .05 level 
of significance. Kruskal-Wallis ANOVA determined that 5 of 
the 10 questions on the Treatment Response Questionnaire 
showed significance of .05 or lower. The chi-square value 
for each significant question showed a statistically 
significant relationship between the responses given by the 
MFR group and the responses given by the US group at a .05 
level of significance.
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INTRODUCTION
Fascia is an elastocollagenous connective tissue in 
which muscles, nerves, blood vessels, lymph vessels and 
bones lie.1 Connective tissue is found in the interstitial 
tissues of all organs, and forms the membranes through 
which osmotic processes of cell nutrition and elimination 
take place.1 Fascia courses all the way to the cellular 
level to separate, support, and protect structures and thus 
may inhibit cellular metabolism if injured or distorted.1
Fascia plays an important role in the normal function 
of the body and may be the cause of disease if altered from 
normal alignment.1'2 Bonica reports that interruptions in 
the normal coursing of fascia can be manifested as symptoms 
of pain, muscle spasm, limitation of range-of-motion, 
vasomotor changes, sweating, and weakness.3 Travell states 
that while myofascial trigger points can be caused by 
chronic visceral disease or emotional stimuli, a myofascial 
trigger area can provoke conditions such as a cardiac 
ectopic rhythm and may be the reason for the pain 
associated with disc syndrome after surgery has been done 
to excise the bulging disc.4 Also, alterations of the 
fascia due to postural imbalance, gravitational pull, 
inflammatory processes, and trauma may be causes of 
physiological malfunction.1
Myofascial pain and dysfunction are commonly 
overlooked by examiners.,5 A patient may be experiencing 
musculoskeletal pain patterns related to fascia but because
1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2the pain does not follow a dermatomal reference zone or 
because various diagnostic test
results are negative, patients are left untreated. Due to 
continual pain or discomfort, the patient seeks a second 
opinion only to be informed that the source of this bizarre 
pain pattern is emotional.
Bonica writes that the identification of myofascial 
pain syndromes is supported when the pain distribution is 
not dermatomal nor following peripheral nerve distribution, 
when movement augments the pain, and usually when no 
sensory nor reflex changes are noted.3 In myofascial 
conditions, Travell explains that neurological deficits are 
not observed unless a muscle that contains a trigger point 
compresses a peripheral nerve, and then inconsistent 
sensory and motor testing will result.4 Travell supports 
the diagnosis of myofascial problems through the 
identification of trigger points. Trigger points are 
"small hyper-irritable regions in muscles from which 
impulses bombard the central nervous system and can give 
rise to referred pain".5 Active trigger points meet the 
criteria of being tender to palpation, producing a "jump 
response" upon palpation, and displaying weakness in the 
muscle containing the trigger point upon active 
contraction.3-6 Bonica defines myofascial trigger points 
as "hypersensitive regions in muscle or connective 
tissue".3 Another explanation of trigger point is "a sign 
or symptom which remains unnoticed by the patient that must
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3be evoked by a stimulus".7 The stimulation used to locate 
trigger points can be palpation or ultrasound and high
voltage galvanic stimulation.8
The patient response to location of a trigger point is 
a localized deep tenderness in a palpably firm band of 
muscle with a low threshold to deep pain.8 Nielsen
describes the area of the stimulated trigger point to which 
pain is referred as a reference zone.7 Within the 
reference zone of pain, it has been found that a
vasodilatation may occur as the trigger points are
stimulated or treated.8 The vasodilatation may be due to 
the release of fascia the capillary beds are coursing 
through, thus causing a freeing of vessels and allowing a 
free flow of blood.1'8 To re-emphasize the fascial 
relation to circulation and to accentuate to the examiner 
the possible vasomotor responses a patient may experience 
with trigger point stimulation, clinicians should be aware 
that "manipulation of soft tissue and corrective posture 
techniques are of utmost importance in maintaining adequate 
venous dra inage."1
As described in the literature, myofascial pain 
treatments placed emphasis on manual mobilization of 
fascial structures3-6'10-15 and on ultrasonic heating of 
the fascial structures.15'16 Travell reports that 
stretching of the myofascial trigger point is an adequate 
method to treat painful trigger points.10 Sola and Kuitert 
have cited that heat and deep friction massage aid the
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4treatment of myofascial trigger points after a local 
injection of saline.13 Griffin and Karselis state that 
treatment with ultrasound will alter connective tissue 
structures such as fascia so as to increase range-of- 
motion, increase tendon extensibility, and relax skeletal 
muscle.15
Myofascial release is noninvasive manual stretching 
and manipulation of fascial trigger points. In this study, 
trigger points will be located by palpation. Trigger 
points are identified when the patient describes a sharp 
sensation of pain when the soft tissue is palpated. 
Travell explains that the sharp feeling of pain is a result 
from palpation of a band of fibers which have been 
injured.4 Simmons writes that massage and thumb pressure 
can decrease the irritation caused by a trigger point.14
This study assumes that specific injury to the 
musculoskeletal system can cause a fascial disarrangement 
and cause myofascial trigger points which can be located 
with palpation. Upon injury to a muscle, the body protects 
itself from aggravating the injured area by splinting the 
site with muscle spasm. Simmons reports that if the muscle 
sarcoplasmic reticulim is injured, it will release calcium 
and the calcium will act together with adenosine 
triphosphate to provoke local contractile activity.5 
Because of the sustained muscle contraction, and because 
fascia hardens with trauma,5 the actin and myocin fibers 
will become shortened. Thus, a disarrangement in the
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5fascia can occur and cause an active trigger point 
resulting in immediate pain.4
With this background in mind, the purpose of this 
study was to examine whether myofascial release techniques 
consisting of cutaneous fascial stretching, unwinding, deep 
pressure '■o trigger points, cranial base release, and 
thoracic inlet, respiratory, and pelvic diaphragm release 
are more effective than ultrasound therapy to treat 
musculoskeletal pain.
The hypothesis for this study is that myofascial 
release when compared to ultrasound will result in greater 
pain relief, measured by pre and post treatment analog pain 
scales, decrease number of trigger points in the affected 
soft tissue examined by palpation, increase active range- 
of-motion of the involved joint, measured by pre and post 
goniometric measurements, and provide a greater subjective 
measure of patient improvement for overall patient 
effects, measured by a Treatment Response Questionnaire.
METHODS
Subjects
Patients with the complaint of pain resulting from 
musculoskeletal injury were selected for this study. A 
patient was admitted to the study only if he met the 
following criteria: l. trigger points can be located with 
palpation; 2. patient has muscle shortening resulting in 
active range-of-motion limitation not caused by bony
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6blockage; 3. patient demonstrates from evaluation and 
questioning no history of connective tissue disease, 
rheumatoid arthritis, central nervous system damage, mental 
illness, malignancy, or unhealed fractures; and 4. patient 
is between 20 and 50 years old.
Thirty-three patients meeting the above criteria were 
admitted to the study. There were 13 men and 20 women. 
The mean age was 38 years with a range of 22 to 50 years. 
After an explanation of the study was given, a consent form 
was signed by each subject. All patient conditions were 
evaluated by the same physical therapist. Twenty-eight 
patients were randomly placed in treatment Group A 
(myofascial release) or in treatment Group B (ultrasound). 
Five of the 33 patients were specifically referred to 
physical therapy for myofascial release or ultrasound. 
These subjects were placed into their referred groups 
without regard to random assignment. Data were collected 
upon relief of all pain symptoms or after the patient had 
experienced 10 treatments, whichever came first. Each 
patient's physical therapy was completed within a four week 
period.
Procedure
In the evaluation of each patient's condition, the 
following data were recorded: 1. the active range-of-
motion of the joint with the most limitation caused by 
musculoskeletal pain; and 2. the number of trigger points
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7found upon palpation of the area in which the patient 
complained of pain. The number of trigger points, within a 
measured area, producing a sharp pain upon palpation was 
recorded by the researcher and a second physical therapist. 
The two numbers were averaged for data purposes. This 
second trigger point palpation by another therapist was 
done to increase the consistency of measurement of the 
trigger point number being used for statistical analysis. 
Trigger point palpation was done by the same physical 
therapists throughout the study. The patient then marked a 
horizontal pain scale to indicate pain perception at the 
time of the initial evaluation.17
Patients placed in the MFR treatment group received 20 
minutes of myofascial release. Myofascial release is 
noninvasive passive stretching of restricted fascia. 
Fascial techniques used in this study include gentle 
cutaneous fascial stretching, relieving fascial mal­
alignment by active assist joint movement (unwinding), deep 
pressure stretching applied specifically to active and 
latent trigger points, gentle separation of the atlas from 
the occiput when patient symptoms are specific for spinal 
musculoskeletal involvement (cranial base release), and re­
alignment of transversely oriented fascia (thoracic inlet, 
respiratory, and pelvic diaphragm releases) when these 
transverse planes are affected by musculoskeletal 
symptomology.
Patients placed in the US treatment group received a 7
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8minute ultrasound at 1.7 W/cm2 per 25 square inch area. 
This intensity was chosen because through experience in 
treating trigger points with ultrasound an increase in 
patient discomfort was reported with intensities beyond 1.7 
W/cm2. The Mettler ultrasound machine was used for each 
treatment and was calibrated prior to beginning the study.
After each therapy session, the patient was instructed 
to continue with his usual daily routine as tolerated. No 
special instructions were given except to patients 
suffering with low back pain. These patients were 
instructed not to lift objects greater than 10 pounds, not 
to flex spine forward, or rotate spine, and to bent the 
knees not the back when picking objects off the floor.
Once the patient had relief of all pain, or the 
patient had completed 10 treatments, physical therapy was 
stopped and the patient's condition re-evaluated. The 
physical therapist re-evaluated the patient's condition and 
recorded the active range-of-motion most limited in the 
initial evaluation, and the number of trigger points 
activated with palpation in the pained area. Again the 
number of trigger points was recorded by the researcher and 
a second physical therapist, and these numbers were 
averaged. Each patient was asked to mark a horizontal pain 
scale describing the pain perception after therapy ended. 
Each patient also completed a Treatment Response 
Questionnaire consisting of 10 questions related to 
progress toward becoming pain free, overall improvement,
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9freedom of joint movement, and ability to perform daily 
living activities. The Treatment Response Questionnaire 
was designed so that responses were given on a point scale 
of improvement from one (0% improvement) to five (100% 
improvement). Prior to giving a patient this
questionnaire, it was reviewed by four typical patients not 
admitted to the study and by four physical therapists to 
assure that each question was understandable and that each 
question was an adequate measure of progress. See table 1 
for a summary of the research procedure.
This research procedure was approved by The Human 
Subject Review Committee of Community Health Professions 
and Physical Therapy, Old Dominion University.
Data Analysis
Statistical analysis included calculation of a Mann- 
Whitney U value to determine if were are statistically 
significant differences of mean rank for percent changes in 
range-of-motion, trigger point number, and pain scale 
measurement. The Mann-Whitney U Test also calculated mean 
rank values for each group's change in range-of-motion, 
change in trigger point number, and change in pain scale 
measurement to determine the direction of level of 
significance at .05 level of significance. A Mann-Whitney U 
value was also calculated to determine the frequency of 
patient response toward 'most improvement' on the Treatment 
Response Questionnaire between treatment groups.
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Kruskal-Wallis H values were computed to determine if 
percent change in trigger point number and percent change 
in pain scale measurements were statistically significant 
at .05 level of significance. Kruskal-Wallis was also used 
to determine which questions in the Treatment Response 
Questionnaire are statistically significant at a .05 level.
The t values were calculated for between group pre 
trigger point number, between group post trigger point 
number, and within group change in trigger point to 
determine if there was a statistical significance at a .05 
level.
Confidence intervals were calculated to address 
whether between group pre range-of-motion measurements and 
between group post range-of-motion measurements are 
statistically significant at .05 level of significance.18 
Confidence limits for change in range-of-motion were 
calculated to determine if there are
statistically significant differences between group means 
at .05 level of significance.18
Chi-square values were calculated to show the 
frequency of patient responses given for each significant 
question on the Treatment Response Questionnaire, and to 
determine if there is a statistically significant 
relationship between the responses given by the MFR group 
and the responses given by the US group at . 05 level of 
significance.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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RESULTS
The t-test was used to address the hypothesis: MFR 
will provide a greater decrease in trigger point number 
from pre to post treatment when compared to US. The t 
value for between group pre trigger point number (2.63), is 
larger than the tabled value of 2.06. The t value for 
between group post trigger point number (0.76), is less 
than the tabled value of 2.06. This means that there is a 
statistical significant difference between group pre 
trigger point values. There is no statistical significant 
difference between group post trigger point values. The 
within US group t value is 0.09 for change in trigger point 
number. The within MFR group t value is 1.94 for change in 
trigger point number. Neither the MFR group change in 
trigger point number nor the US group change in trigger 
point number is significant at the .05 level. See Table 2 
for the t value, degrees of freedom, and the level of 
significance for each treatment group change in trigger 
point number. The t test does not support the hypothesis.
Because the results of the t test supported that the 
MFR subjects and the US subjects were two independent 
samples prior to the application of treatment, the Mann- 
Whitney U value was calculated to address the hypothesis: 
MFR will provide a greater decrease in the number of 
trigger points from pre to post treatment when compared to 
US. The U value of 47 is smaller than the tabled value of 
89. This means that the MFR group outranked the US group
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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47 percent when ranking the percent change in trigger point 
number from pre to post treatment. The mean rank of 
percent change in trigger points from pre to post treatment 
for the MFR group is 23. The mean rank of percent change 
in trigger points from pre to post treatment for US is 12. 
These computations for percent change in the number of 
trigger points between groups support the hypothesis in 
that a statistically significant difference is present 
between treatment group means at .05 level of significance. 
See figures l and 2 for raw data bar graph display.
Kruskal-Wallis one-way analysis of variance was 
computed to address standard deviations for means between 
groups and within groups on percent change in trigger point 
number from pre to post treatment, and to determine if 
there was statistical significance between group change in 
trigger point. The mean trigger point number palpated 
prior to MFR intervention was 24.7, with a standard 
deviation of 21.2. The mean trigger point number palpated 
post MFR was 14.0, with a standard deviation of 18.7. The 
mean trigger point number palpated prior to US intervention 
was 10.7, with a standard deviation of 5.8. Mean trigger 
point number post US application was 10.3, with a standard 
deviation of 6.9. There is a decrease of 10.7 in the 
trigger point means from pre to post MFR treatment, and a 
decrease of 0.4 in the trigger point means from pre to post 
US treatment. See Table 3 for the minimum and maximum 
changes in trigger point number which could occur from pre
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to post treatment within each treatment group. The 
Kruskal-Wallis H value for percent change in trigger point 
number from pre to post treatment was 6.12. Because this 
value is larger than the tabled value of 3.84 there is 
statistical significance at a .05 level. It appears that 
MFR results were better than ultrasound results in change 
in trigger point because the sum of the rankings for MFR 
(T=203.34) was lower than the sum of the rankings for US 
(T=357.66). See table 4 computation values specific to 
Kruskal-Wallis H values. These results support the 
hypothesis.
The Mann-Whitney U value was calculated to address the 
hypothesis: MFR will provide greater pain relief as
measured by an analog scale when compared to US. The U 
value of 79 is smaller than the tabled value of 89. This 
means that the MFR group outranked the US group 79 percent 
when ranking the percent change in the pain scale 
measurement from pre to post treatment. The mean rank of 
percent change in pain from pre treatment to post treatment 
for the MFR group is 20.6. The mean rank of percent change 
in pain from pre to post treatment for the US group is 
13.7. These computations for change in pain scale 
measurement within groups supported the hypothesis for a 
statistically significant difference between treatment 
group means at .05 level of significance. See figures 3 
and 4 for raw data bar graph display.
Kruskal-Wallis one-way analysis of variance was
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computed to address the hypothesis: MFR will provide
greater pain relief as measured by an analog scale when 
compared to US. The mean pre pain scale measurement for US 
is 6.2 cm, with a standard deviation of 1.8 cm. The mean 
pre pain scale measurement for MFR is 6.9 cm, with a 
standard deviation of 2.0 cm. The mean post pain scale 
measurement for US is 5.06 cm, with a standard deviation of 
2.4 cm. The mean post pain scale measurement for MFR is
3.8 cm, with a standard deviation of 3.0 cm. This shows a 
decrease of 1.1 cm in the pain scale measurement means from 
pre to post US treatment and a decrease of 3.1 cm in the 
pain scale measurement means from pre to post MFR 
treatment. See Table 5 for minimum and maximum pain scale 
values from pre treatment to post treatment for both 
groups. The Kruskal-Wallis H value for between group 
change in pain scale measurement from pre to post treatment 
is 8.30. This value exceeds the tabled value of 3.84 at 
.05 level of significance. It appears that MFR results 
were better than ultrasound results in change in pain scale 
measurement because the sum of the rankings for MFR 
(T=192.00) was lower than the sum of the rankings for US 
(T=369.00). See table 6 computation values specific to 
Kruskal-Wallis H values. These results support the 
hypothesis.
The Mann-Whitney U value was calculated to address the 
hypothesis: MFR will provide a greater increase in range- 
of-motion as measured with a goniometer pre treatment and
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post treatment when compared to US. The U value of 46 is 
smaller than the tabled value of 89. This means that the 
MFR group outranked the US group 46 percent when ranking 
the percent change in range-of-motion from pre to post 
treatment. The mean rank of percent change in range-of- 
motion from pre to post treatment for the MFR group is 23. 
The mean rank of percent change in range-of-mction from pre 
to post treatment for the US group is 12. These 
computations for change in range-of-motion support the 
hypothesis and suggest a statistically significant 
difference between treatment group means at .05 level of 
significance. See figures 5 and 6 for raw data bar graph 
display.
Confidence intervals were calculated to address 
whether or not between group pre range-of-motion
measurements and between group post range-of-motion
measurements are statistically different.18 The range of 
values for pre range-of-motion measurement from the lower 
confidence limit (-0.42) to the upper confidence limit 
(0.66) includes zero. This means that the obtained 
difference between means could have been due to chance, and 
therefore the difference between pre range-of-motion means 
is not statistically significant at .05 level of
significance.18 The range of values for post range-of- 
motion measurements from the lower confidence limit (-0.41) 
to the upper confidence limit (0.58) includes zero. This 
means that the obtained differences between means could
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have been due to chance, and therefore the difference 
between post range-of-motion means is not statistically 
significant at .05 level of significance.18
The mean rank of change in range-of-motion for each 
treatment group was calculated to figure the confidence 
limit for the difference between two means from unmatched 
groups. The mean rank for change in range-of-motion for 
MFR is 22.6, with a standard deviation of 4.1. The mean 
rank for change in range-of-motion for US is 11.7, with a 
standard deviation of 2.5. The confidence limits for the 
difference between the change in range-of-motion from 
unmatched groups are upper = 13.3 and lower = 8.5. This 
range of values does not include zero. The difference in 
change of range-of-motion between the treatment groups is 
statistically significant at .05 level of significance.18 
This difference between the means can be expected to occur 
again in favor of the MFR treatment because the confidence 
limits are statistically significant, and because the mean 
rank for change in range-of-motion is higher for MFR as 
opposed to US.18 See Table 7 for data involved in 
calculating the confidence limits for the difference 
between two means from unmatched groups. The confidence 
limit computations for change in range-of-motion between 
groups support the hypothesis.
Standard deviations were computed from the mean 
percent change in range-of-motion from pre to post 
treatment. Measurement of variation within the MFR group
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revealed a mean percent change in range-of-motion of 78.3 
percent, with a standard deviation of 60.8. All of the 16 
patients in the MFR group experienced an increase in range- 
of-motion post treatment. Change in range-of-motion was
2.9 percent to 170.0 percent for the MFR group. The 
percent change in range-of-motion for the US group revealed 
a mean of 15.8 percent, with a standard deviation of 26.8 
percent. Of the 17 patients in the US group, 10 
experienced an increase in change of range-of-motion post 
treatment. Change in range-of-motion was 1.2 percent to 
60.0 percent for the 10 patients in the US group. The 
remaining seven patients in the US group experienced a 
decrease in change of range-of-motion post treatment. 
Percent change in range-of-motion was 2.9 percent to 16.7 
percent for the remaining seven patients in the US group. 
See Table 8 for a summary of these results. Although the 
mean percent change in range-of-motion between groups was 
markedly different, the standard deviations from each mean 
were too disperse to identify any difference between group 
change in range-of-motion measurements. The hypothesis is 
not supported.
The Mann-Whitney U value was calculated to address the 
hypothesis: MFR will provide greater subjective patient
improvement as measured by the Treatment Response 
Questionnaire when compared to US. The U value of 55 is 
smaller than the tabled value of 89. This means that the 
MFR group outranked answers in the US group 55 times. The
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mean rank of responses for the MFR group is 22 on a scale 
of 1 to 50. The mean rank of responses for the US group is 
12 on a scale of 1 to 50. These computations supported the 
hypothesis and suggested a statistically significant 
difference between group means at .05 level of 
significance.
Kruskal-Wallis one-way analysis of variance was 
computed to determine which questions in the Treatment 
Response Questionnaire are statistically significant. Five 
of the 10 questions showed significance of .05 or lower. 
This means that there are significant differences in the 
ranks of the responses given by each group for 5 of the 10 
questions at .05 level of significance. These questions 
were one, four, five, six, and nine and addressed 
improvement to changes in pain, changes in movement, and 
improvement in ability to perform daily activities. See 
Table 9 for level of significance for each statistically 
significant question and degrees of freedom. The remaining 
five questions were eliminated from statistical computation 
because of not meeting the .05 level of significance.
Chi-square was calculated to investigate if 
frequencies of responses for each significant question were 
different, and to test the hypothesis of MFR will provide 
greater subjective patient improvement as measured by the 
Treatment Response Questionnaire when compared to US. See 
Table 10 for chi-square values and frequency data for each 
significant question. The chi-square value for each
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question supported that there is a statistically
significant relationship between the responses given by the 
MFR group and the responses given by the US group at .05 
level of significance.
DISCUSSION
Although 85 percent of the subjects were randomly 
placed into a treatment group, a normal distribution of 
patients cannot be assumed because of sampling size. 
Sampling size could have been increased if the criteria to 
enter the study had not been so stringent. However, better 
control was maintained by eliminating extraneous variables 
that may have been introduced by patient's conditions
outside the criteria for admission to the study.
A statistically significant difference between mean 
percent change in the number of trigger points from pre to 
post treatment is supported by the Mann-Whitney U test. 
The Kruskal-Wallis H value for percent change in trigger 
point from pre to post treatment supported that MFR
subjects appeared to make greater progress than US 
subjects. The t-test for trigger point data supported no 
statistical significance for within group change in trigger 
point at a .05 level. The MFR group change in trigger
point number was significant at a 0.10 level opposed to the 
US group change in trigger point number at a 0.50 level of 
significance. Refer to table 3 for summary of these 
results. In the clinical setting, clinicians may wish to
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consider the substantial difference in change in trigger 
point number for MFR versus US in making treatment 
decisions.
All of the MFR subjects had a decrease in the number 
of trigger points from pre to post treatment. Five of the 
US subjects had an increase in the number of trigger points 
and two remained the same (Figs. 1 & 2). With the US 
subjects who did make a change in the number of trigger 
points toward improvement, there was a mean decrease of 
only 0.20 with US, opposed to a mean decrease of 10.7 with 
MFR.
The Mann-Whitney U Test supported that there is a 
statistical significance between mean percent change of the 
pain scale measurement from pre to post treatment at .05 
level of significance. This statistical significance is in 
favor of the MFR group because there is a greater mean rank 
of percent change in the pain scale measurement for MFR 
(20.6) compared to US (13.7). The Kruskal-Wallis H value 
appeared to show a greater change toward improvement from 
pre to post treatment in the MFR group at .05 level of 
significance.
Confidence limit calculation for range-of-motion data 
showed that there is no statistical differnce between group 
pre range-of-motion scores and between group post range-of- 
motion scores. This is expected because the subjects in 
one treatment group were unmatched from the other treatment 
group. Confidence intervals supported a statistical
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significance for within group changes in range-of-motion. 
This indicates that the changes in range-of-motion would 
probably occur at .05 level of significance with both US 
and MFR if the study was reproduced. But is one treatment 
more significant over the other in the treatment of 
musculoskeletal pain? The confidence interval (13.3 to 
8.5) calculated from the mean rank values of US (11.7) and 
MFR (22.6) does not include zero. This means that there is 
less than five percent probability that a difference as 
large as the obtained 4.8 (13.3 minus 8.5) point advantage 
for the MFR group could have resulted from chance variation 
between the groups.18 There is a high probability that the 
MFR subjects would display greater change in range-of- 
motion at 95 percent confidence if this study was performed 
again.
The standard deviations computed were too dispersed 
about the mean to suggest statistical significance for 
change in range-of-motion measurements. The fact that some 
patients in the US group experienced an increase in change 
of range-of-motion while others experienced a decrease in 
change of range-of-motion, caused the standard deviation to 
be greater than the mean percent change of range-of-motion. 
See raw data display of measurements for each group in 
Figures 5 and 6.
Both the Mann-Whitney U Test and chi-square 
computations supported a statistically significant 
relationship between the responses given by the MFR group
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compared to the US group. The mean rank of responses for 
the MFR group fell at the middle of a 50 point scale. This 
suggested that MFR subject mean responses averaged 
"moderate improvement". The mean rank of responses for the 
US group fell at the lower to middle end of a 50 point 
scale. This suggested that US subject mean responses 
averaged "minimal to moderate improvement".
Overall subjective changes from pre to post treatment 
were more satisfying for the MFR subjects. This may be 
partially due to the amount of attention given to each 
subject by the physical therapist. MFR subjects were given 
20 minutes of the therapist's time as opposed to 7 minutes 
of the therapist's time for the US subjects.
Further research is suggested in comparing MFR to 
another manipulatory physical therapy treatment rather than 
a non-manipulatory treatment such as US.
CONCLUSION
In this investigation, it was found that patients from 
both treatment groups had increased in active range-of- 
motion, decreased in trigger point number, and decreased in 
pain. This finding supported individual patient successes 
in both treatment groups. Changes showing no progress are 
also present within both treatment groups. Positive and 
negative changes in treatment results can be directly seen 
by looking at the bar graphs in figures one through six. 
The results of this study supported that mean differences
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
23
in between group pain scale measurement, and mean 
differences in between group change in range-of-motion are 
statistically significant in favor of the MFR treatment.
This study by no means emphasizes a sole use of 
myofascial release nor ultrasound in patient treatment, but 
comparisons of modalities must occur to offer support to 
clinicians as to their successfulness.
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Figure 1 - Pre to Post Trigger Point Changes for 
Myofascial Release
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SUMMARY OF PROCEDURES
Evaluat i on 
Consent Form
MFR
a. pre-treatment ROM
b. pre-treatment #TP
c. pre-test (pain scale)
MFR Treatment
a. post-treatment ROM
b. post-treatment #TP
c. post-test (pain scale)
d. give Treatment Response 
Quest i onnai re
US
a. pre-treatment Rom
b. pre-treatment #TF'
c. pre-test (pain scale)
a.
b.
US Treatment
post-treatment ROM 
post-treatment #TP 
post-test (pain scale) 
give Treatment Response 
Questionnaire
IF LITTLE OR NO 
PROGRESS, RE-EVALUATE 
AND CHANGE TREATMENT
Table 1
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t-TEST CALCULATIONS FOR TRIGGER POINT
MEASUREMENTS
MYOFASCIAL ULTRASOUND
Pre => Post Pre => Post
t VALUE 1.94 0.09
D.F. 29
LEVEL OF 
SIG. 0. 10 0.50
Table 2
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KRUSKAL-WALLIS CALCULATIONS FOR TRIGGER POINT
MEASUREMENTS
MYOFASCIAL ULTRASOUND
Pre Post Pre Post
N
MEAN
STD DEV
MIN
MAX
----------
16 16 17 17
24.7 14.0 10.7 10.5
21.2 18.7 5.8 6. w
4.5 0.0 2.0 0.0
82.0 52.0 26.5 27.5
Table 3
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KRUSKAL-WALLIS CALCULATIONS FOR 
CHANGE IN TRIGGER POINT NUMBER
MYOFASCIAL ULTRASOUND
T
Hcauc
Htable
203.34 357.66
6. 12
3.84
Table 4
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KRUSKAL-WALLIS CALCULATIONS FOR PAIN SCALE
MEASUREMENTS
MYOFASCIAL ULTRASOUND
Pre Post Pre Post
N
MEAN 
STD DEV 
MIN 
MAX
16 16 17 17
6.9 10 • 00 6. 1 5. 1
2.0 2.0 1.8 2. 4
2.6 0. 1 3.4 1.7
9. 1 10.0 9.0 8.9
Table 5
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KRUSKAL-WALLIS CALCULATIONS FOR
CHANGE IN PAIN SCALE MEASUREMENT
MYOFASCIAL ULTRASOUND
T
Hcalc
Htabl*
192.00 369.00
8.30
3.84
Table 6
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INPUT DATA FOR CALCULATING CONFIDENCE LIMITS FOR THE 
DIFFERENCE BETWEEN CHANGE IN RANGE-OF-MOTION 
MEANS FROM UNMATCHED GROUPS
Mean o f 
Change in ROM STD. DEV. N
t-value for 
.05 LOS
US-group X
I
c D II • Nl 3ua = 2•50 17 2.04
MFR-group XiirR — 22 • 6 SnrR = 4.13 16 2. 04
Table 7
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STANDARD DEVIATION CALCULATIONS FOR 
MEAN PERCENT CHANGE IN RANGE-OF-MOTION
MYOFASCIAL ULTRASOUND
"/. Change F're=>Post '/. Change Pre=>Post
N
MEAN 
STD DEV 
MIN 
MAX
IS 17
78.3 15.8
60. 8 26.8
+2.9 -16.7 •
+170.0 +60.0 —
* 7 of the 17 patients experienced a decrease
** 10 of the 17 patients experienced an increase
Table 8
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PATIENT RESPONSE QUESTIONNAIRE: 
SIGNIFICANT QUESTION DATA
Q1 <34 05 06
■i
03
D.F. 3.0 3.0 4.0 3.0 4.0
LEVEL 
Uh 
SIG.
0.02 0.01 0.003 0.0004 0.005
Table 9
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CHI-SQUARE VALUES AND FREQUENCY DATA 
FOR SIGNIFICANT QUESTIONS
QUESTION
Yes, 
no 
pai n 
now
Much
less
pain
Pain
mod.
reduce
A
little
less
pain
Pai n 
same 
as 
before
1. Do you feel 
your pain is 
less after going 
through 10 
physical therapy 
treatments?
CHI-SQUARE 9.59
MFR
0
MFR
S
MFR
4
MFR
4
MFR
0
US
0
US
5
US
0
US
9
US
3
100*/. 757. 507. 257. 07.
4. How much 
i mprovement 
in movement 
have you 
experienced?
MFR
0
MFR
8
MFR
6
MFR
2
MFR
0
US US US US US
CHI-SQUARE 10.91 0 1 8 3 5
1007. 
i mprov.
Much 
i mprov.
Mod.
improv.
Min.
improv.
No 
i mprov.
5. Are you able 
to perform 
your activities 
of daily living 
better?
MFR
0
MFR
5
MFR
10
MFR
1
MFR
0
us' US US US US
CHI-SQUARE 15.85 1 5 1 7 3
Table 10 
(continued)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
42
CHI-SQUARE VALUES AND FREQUENCY DATA 
FOR SIGNIFICANT QUESTIONS
6. Do you feel 
physical 
therapy has 
helped your 
condition?
CHI-SQUARE 18.41
Yes,
Total
recov.
Has 
helped 
a lot
Helped
mod.
amount
Helped
little
amount
Not
at
all
MFR
0
MFR
9
MFR
7
MFR
0
MFR
0
US
0
US
4
US
1
US
10
US
2
9. Are you
feeling better 
about getting 
back to normal 
now that you 
have completed 
10 physical 
therapy 
sessions?
CHI-SQUARE 14.92
Yes
Much
better
Mod.
better
Little
better No
MFR
3
MFR
6
MFR
6
MFR
1
MFR
0
US
1
US
3
US
1
US
10
US
2
Table 10
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LOUISE OBI Cl MEMORIAL HOSPITAL • SUFFOLK. VIRGINIA 23434
Procedure for Research Participation
The physical therapist has evaluated you and has concluded that you Beet 
the criteria to be included in a research study. Both ayofascial release 
treatment and ultrasound treatment have been clinically found to decrease pain 
and function but conclusive research has not been done concerning the nost 
effective treatment for your painful condition. Thus, the purpose of this study 
is to help determine the aost effective physical therapy to aid in the treatment 
of your pain and limitation.
If you sign the consent form to be Included in this study, you will be 
randomly placed in treatment group A consisting of passive stretching called 
myofascial release, or treatment group B consisting of a deep heat called ultra­
sound. You will be asked to mark a pain scale describing the Intensity of your 
pain. Then you will be placed through physical therapy sessions until your pain 
has completely subsided or you have reached a maximum of ten treatments. Next, 
you will be asked to complete a subjective rating scale consisting of ten randomly 
arranged questions. You will also be asked to again mark a pain scale describing 
the intensity of your pain at the end of your therapy. Lastly, the same physical 
therapist will re-evaluate your condition and document data specific for the re­
search.
Please relay any questions concerning the above procedure to your physical 
therapist. You are not obligated to participate in this research. If you agree 
to participate, you will be Informed of the outcome of this study if you desire. 
This research procedure has been evaluated and approved by the Old Dominion Uni­
versity Human Subjects Review Committee of the Department of Community Health 
Professions and by the Administration of Louise Oblci Memorial Hospital.
T E LE P H O N E  804 / 539-151 I •  P . O .  BOX 1100
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MfOiHgD COKW  rtww
Pr#jn*. K< ?■»: _________ ____ ____________________________
Iw t it  i( ilo r( s)
BCTI:
ThH 1* to certify that I . hereby
agree to participate u  i  volunteer In i  scientific Invest1getIon is i  p irt 
of the educational end research program of Old Dominion University, under 
the supervision of .
, (Faculty Person/Principal Investigator)
The Investigation and the nature of my participation have been de­
scribed and explained to me, and 1 understand the explanation. (See attach* 
*• ed o k  page abstract.) I understand that 1 an one of Individuals par­
ticipating In this research project. I  further understand that I may with­
draw from the project at any tine, without penalty or prejudice.
I* have been afforded an opportunity to ask questions concerning the 
purpose of this project and a ll such questions have been answered to my sat­
isfaction. 1 understand that should I have additional questions In the fu­
ture about this project or the uniter in which I t  Is conducted, I u y  con­
tact _ _ _ _ _ — — __«  i
(Faculty Person/Principal Investigator) (Telephone Huber)
1 mderstand that I  an free to withhold any answer to specific Itcus or 
questions 1n any questionnaire submitteu to u  for this project. I under­
stand that any data or answers to questions will remain confidential with 
regard to uy identity. 1 further understand that no data which can be Iden­
tified  with me will be released to persons outside the research tewr without 
the team firs t obtaining my written permission.
1 acknowledge that 1 was informed about any possible risks to my health 
and well being that u y  be associated with my participation in this re­
search (see attached abstract). I understand that no -medical or psycho­
logical assistance will be ude available to me by either Old Dominion Uni­
versity or any member of the research tea* as a result of any physlcial or 
•notional harm 1 nay experience as a result of this research project.
I acknowledge that I have been advised of how 1 may obtain a copy of 
the results of this research project and that upon my making such a result, 
a copy w ill be provided without charge.
1 have been tnformed that 1 have tne right to contact the 51 •* Dominion 
University Institutional Review Board for the Protection of Hume? Subjects 
should 1 wish to express any opinions regarding the conduct of U.'.i study.
—————— — — — — — — ——  Oate:
« n > ia tiir*  of Volunteer
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TABLE I
Treatment Group "A" Data: Myofaaclal Release
BEFORE TREATMENT AFTER TREATMENT
Patient's Name
i
Number of Trigger 
Pts. Palpated and 
Body Part (see body 
chart)
AROM of Most 
Limited Range
Pain Scale 
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Treat. 
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VISUAL P A W  SCALE
Instructions: Mark on the scale below the ususl level of jour pain.
FAIN AS
» 0  P A W  ----    BAD AS IT
COULD BE
1 10
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P A T IE N T  RESPONSE Q U E S T IO N N A IR E  ^  * Activities of Daily Living 
1. Do you feel your pain is less after going through 10 physical therapy treatments?
_______l________i__ :_______i_________ i____
Yes - no pain Much less pain Pain moderately A little less No-pain feels the
at all ^ed pain same as before
2. Do you feel your overall condition has Improved after 10 physical therapy sessions?
__________________ I__________________ I______________
Total Recovery Much Improvement Moderate Improvement Minimal Improv. No Improvement
3. Are you able to move more freely after 10 physical physical therapy sessions?
No f* in freedom Minimal in Moderate ^  in Much Improvement Am back to normz
of movement movement movement improvement
4. How much improvement in movement have you experienced?
0% 25% 50% 75% 100%
5. Are you able to perform your ADL better?
No Improvement Minimal Improv. Moderate Improvement Much Improvement Can perform ADL 
in performing with no problems
ADL
6. Do you feel physical therapy has helped your condition?
Am totally Has helped a lot Has helped a mod. Has helped a little No-Not at all
Recovered amount bit
7. How much improvement in pain have you experienced?
0% 25% 50% 75% 100%
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8. Are you in more comfort when functioning through &BL ?
No-Not At All A little Moderate Much More Comfort Yes-No discomfoi
in comfort in comfort At All
9. Are you feeling better about getting back to normal now that you have experienced 
10 physical therapy sessions?
Definately Yes Much Better Feeling a moderate A little bit better Definately No
amount better Feel I don't
have a good 
chance to get 
better
10. I am able to perform (major movement complaint) ________________________
100% better 75% better 50% better 25% better 0% better
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LOUISE OBICI MEMORIAL HOSPITAL • SUFFOLK, VIRGINIA 23434
M E M O R A N D  U M
TO: Gary W. Smith, Director of Rehabilitative Services
FROM: D. Bishop, R.P.T. ^
DATE: March 25, 1985
RE: Initiation and Completion of an Experimental Research Study
I would like to undertake an experimental study involving LOMH patients 
suffering with myofascial pain. Conclusive research has not been done con­
cerning the most effective treatment for myofascial syndromes. Thus, the 
purpose of this study is to help determine the most operative physical therapy 
to aid in the treatment of myofascial pain and limitation.
The procedure for research participation will be as follows:
a) Patient will be evaluated by the physical therapist to determine if 
the subject meets the criteria listed below:
1) trigger points can be located with palpation 
— It has been1 less Lliau two w eeks post the initial onset of -pain
3) patient has muscle tension shortening resulting in some active 
range of motion limitation not caused by bony blockage
4) patient denies a history of connective tissue disease, rheumatoid 
arthritis, central nervous system damage, mental illness, 
malignancy, and unhealed fractures
5) patient is between 20-50 years old
b) Written explanation of research study in layman's vocabulary presented 
to patient
c) Patient signs consent form to be kept on file
d) Patient randomly placed in treatment group "A" consisting of myofascial 
release or treatment group "B" consisting of ultrasound
e) Therapist will document objective data such as number of trigger points 
and specific joint range of motion
f) Patient marks a pain scale denoting the patient's perceptive level of 
pain prior to physical therapy
g) Patient placed through treatment until he is better or until he has 
reached ten complete treatments
h) Patient marks a pain scale denoting the patient's perception of pain 
after physical therapy
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i) Patient also asked to answer a questionnaire concerning his perception 
of progress in decreasing his pain and increasing his function 
j) Therapist will document objective data such as number of trigger points 
and specific joint range of motion 
k) If patient has made little or no progress with his designated physical 
therapy, then a re-evaluation will take place and treatment will change 
to better aid the patient's pain and limitation
This study has been provoked because of recognizing that myofascial conditions 
appear to be mal-treated, because previous research has not be completed concerning 
myofascial release and ultrasound in treating myofascial conditions, and because ex­
perimental research will aid in the completion of my masters.
Upon completion of my work, attempQ will be made to get this experimental 
research published at which time Louise Obici Memorial Hospital, Old Dominion University 
and 1 will be recognized.
This study has been evaluated and approved by the Old Dominion University 
Subjects Review Committee.
DB:sh
pc:
Robert R. Everett 
Richard Linneberger
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LOUISE OBICI MEMORIAL HOSPITAL • SUFFOLK, VIRGINIA 23434
M E M O R A N D U M
TO:
(
Dr. Douglas Kells * "
Medical Director of Physical Therapy, President of Medical Staff
FROM: D. Bishop, R.P.T.
DATE: April 16, 1985
RE: Initiation and Completion of an Experimental Research Study
I would like to undertake a research study involving LOMH patients suffering 
with possible myofascial pain. Conclusive research has not been done concerning 
the most effective treatment for myofascial syndromes. Thus, the purpose of this
study is to help determine the most effective physical therapy to aid in the treat­
ment of myofascial pain and limitation.
The procedure for research participation will be as follows:
a) Therapist has on file an "Evaluate and Treat" referral from the patient's
doctor
b) Patient will be evaluated by the physical therapist to determine if the 
subject meets the criteria listed below:
1) trigger points can be located with palpation 
• 2)- it has been less than four weeks post the lnlxial"onset of pain 
3) patient has some active range of motion limitation not caused by 
bony blockage
A) patient denies a history of connective tissue disease, rheumatoid 
arthritis, central nervous system damage, mental illness, malig­
nancy, and unhealed fractures
5) patient is between 20-50 years old
c) Written explanation of research study in layman's vocabulary presented 
to patient
d) Patient signs consent form to be kept on file
e) Patient randomly placed in treatment group "A" consisting of myofascial 
release or treatment group "B" consisting of ultrasound
f) Therapist will document objective data such as number of trigger points 
and specific joint range of motion
g) Patient marks a pain scale grading his perception of pain prior to 
physical therapy
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h) To be consistent with the research protocol, the patient is given 
physical therapy until the patient and physical therapist feel he 
has reach maximal recovery or until the patient has completed 10 
treatments. If after 10 treatments the patient has not recovered 
from his pain and limitation, he will be re-evaluated by the phys­
ical therapist and treatment will be altered. The doctor will be 
notified of any changes in the patient's therapy.
i) Patient marks a pain scale grading his perception of pain after 
physical therapy.
j) Patient asked to answer a questionnaire concerning his perception
of progress in decreasing his pain and increasing his function
k) Therapist will document objective data such as number of trigger
points and specific active joint range of motion
Although ultrasound and myofascial release (a noninvasive manual stretching
and manipulation of fascial trigger points) have each been found to be clinically 
successful physical therapy modalities, there has been no conclusive research com­
pleted supporting the most competent method to treat myofascial condition. This 
research will help physicians and physical therapist better determine the most 
effective therapy to aid a patient suffering from myofascial pain and limitation.
If your patient meets the designated criteria previously listed, please send 
the patient to physical therapy with an "Evaluate and Treat" referral. Once 60 
subjects are treated suffering from myofascial pain, appropriate statistical anal­
ysis will be done to determine the level of significance of the treatment modality 
found most effective. After completion of this experimental research, attempts 
will be made to have the results published in the American Physical Therapy Associ­
ation Journal so that professionals treating patients with myofascial pain and 
limitations will be more aware of the most effective treatment method: ultrasound 
versus myofascial release. This study has been evaluated and approved by the Old 
Dominion University Human Subjects Review Committee of the Department of Community 
Health Professions and the Administration of Louise Obici Memorial Hospital contin­
gent upon the approval of Physical Therapy's Medical Director, Dr. Douglas Kells.
DB:sh
pc: All Medical Staff
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